Table 1.
Clinicopathologic Characteristics and Outcomes of 378 Patients who Underwent Hepatectomy for CLM According to the Pathologic Tumor Response to Preoperative Chemotherapy
| Characteristic or Outcome | All Patients (N = 378) | Major Pathologic Response (N = 217) | Minor Pathologic Response (N = 161) | P* |
|---|---|---|---|---|
| Male sex, n (%) | 212 (56) | 122 (56) | 90 (56) | 0.950 |
| Median age (range), years | 58 (25–85) | 58 (25–85) | 57 (27–82) | 0.490 |
| Mean age (SD), years | 57 (11) | 58 (11) | 57 (12) | 0.490 |
| Median body mass index (range), kg/m2 | 27 (16–48) | 28 (18–48) | 27 (16–48) | 0.912 |
| Mean body mass index (SD), kg/m2 | 28 (6) | 28 (6) | 28 (6) | 0.912 |
| Synchronous CLM, n (%) | 246 (65) | 151 (70) | 95 (59) | 0.033 |
| Rectal primary tumor, n (%) | 105 (28) | 52 (24) | 53 (33) | 0.055 |
| Node-positive primary tumor, n (%) | 267 (71) | 156 (72) | 111 (69) | 0.534 |
| Preoperative chemotherapy for CLM | ||||
| Irinotecan, n (%) | 143 (38) | 59 (27) | 84 (52) | < 0.0001 |
| Oxaliplatin, n (%) | 235 (62) | 158 (73) | 77 (48) | < 0.0001 |
| Bevacizumab, n (%) | 230 (61) | 147 (68) | 83 (52) | 0.001 |
| Cetuximab, n (%) | 21 (6) | 13 (6) | 8 (5) | 0.668 |
| Median number of cycles (range) | 6 (2–36) | 6 (2–32) | 7 (2–36) | 0.103 |
| Mean number of cycles (SD) | 8 (6) | 8 (6) | 9 (7) | 0.103 |
| Two-stage hepatectomy, n (%) | 30 (8) | 19 (9) | 11 (7) | 0.494 |
| Portal vein embolization, n (%) | 47 (12) | 26 (12) | 21 (13) | 0.757 |
| Associated procedure, n (%) | 63 (17) | 31 (14) | 32 (20) | 0.149 |
| Major hepatectomy, n (%) | 259 (69) | 149 (69) | 110 (68) | 0.944 |
| Postoperative complication, n (%) | 107 (28) | 54 (25) | 53 (33) | 0.086 |
| Major postoperative complication, n (%) | 61 (16) | 32 (15) | 29 (18) | 0.390 |
| Median estimated blood loss (range), mL | 300 (0–6000) | 300 (10–6000) | 300 (0–3500) | 0.070 |
| Mean estimated blood loss (SD), mL | 422 (512) | 387 (502) | 468 (523) | 0.070 |
| Blood transfusion, n (%) | 68 (18) | 31 (14) | 37 (23) | 0.030 |
| Median number of CLM (range) | 2 (1–75) | 2 (1–75) | 2 (1–16) | 0.592 |
| Mean number of CLM (SD) | 3 (4) | 3 (5) | 3 (3) | 0.592 |
| Median largest diameter of CLM (range), cm | 2 (1–18) | 2 (1–16) | 3 (1–18) | < 0.0001 |
| Mean largest diameter of CLM (SD), cm | 3 (3) | 3 (2) | 4 (3) | < 0.0001 |
| Median preoperative CEA level (range), ng/mL | 3 (0–1392) | 2 (0–727) | 5 (1–1392) | < 0.0001 |
| Mean preoperative CEA level (SD), ng/mL | 27 (106) | 14 (63) | 44 (143) | < 0.0001 |
| Positive surgical margins, n (%) | 52 (14) | 23 (11) | 29 (18) | 0.033 |
| Postoperative chemotherapy for CLM, n (%) | 260 (69) | 153 (71) | 107 (67) | 0.330 |
*
Comparison of patients with major versus minor pathologic response.
CEA indicates carcinoembryonic antigen; CLM, colorectal liver metastases; SD, standard deviation.